It is difficult to predict prognosis in patients with locoregional well-differentiated (WD) pancreatic neuroendocrine tumors (PanNET). We aimed to examine commonly used stratification systems [World Health organization (WHO) 2004 and 2010 classifications, American Joint Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS) staging, and the Hochwald grading system] for their power in predicting recurrence-free survival (RFS) in these patients. Seventy-five such patients (mean age 56 y, mean followup 79 mo) who underwent resection with sufficient tissue material and follow-up data were studied. RFS was correlated with variable clinicopathologic features and stratified with abovementioned systems. Concordance index (CI) was then calculated. With the WHO 2004 classification, 16, 35, and 24 PanNETs were classified as benign behavior, uncertain behavior, and WD endocrine carcinoma, respectively. By the WHO 2010 classification, 26, 41, and 8 tumors were grade 1, 2, and 3, respectively. Using the Hochwald system, 47 were low grade, and 28 were intermediate grade. The AJCC staging information was complete for 62 patients (13 had the lymph node status Nx) and included: stages IA (19/62), IB (10/62), IIA (10/62), and IIB (23/62). The ENETS staging information was stages I (16/62), IIa (8/62), IIb (14/62), IIIa (0/62), and IIIb (24/62). The average Ki-67 proliferation index (PI) was 8.1%. Factors that predicted RFS included tumor size, nodal metastasis, vascular invasion, perineural invasion, necrosis, mitosis, and Ki-67 PI (all P < 0.01).
W ell-differentiated (WD) pancreatic neuroendocrine tumors (PanNETs) are uncommon neoplasms, with an annual incidence <1/100,000 person-years in the general population. 1, 2 One of the challenges in managing patients with WD PanNET lies in predicting tumor behavior in patients with regional disease (no distant metastasis) at the time of presentation. The pathologic grading systems for PanNET have evolved dramatically in the past decade. In 2002, Hochwald et al 3 proposed a system to stratify WD PanNET into low grade and intermediate grade on the basis of mitotic counts and necrosis. In 2004, World Health Organization (WHO) proposed a scheme to classify WD PanNET [then pancreatic endocrine neoplasm(PENs)] as PEN-benign behavior (BB), PEN-uncertain behavior (UB), and WD endocrine carcinoma (WDCA) on the basis of tumor size, mitotic count, proliferation index (PI), vascular invasion, perineural invasion, gross localization, and metastasis. 3 In 2010, WHO simplified the classification scheme by applying only mitotic count and PI; PanNET was reclassified into WD neuroendocrine tumor (grade 1 and grade 2) and poorly differentiated endocrine carcinoma (grade 3). 4 Besides the histopathologic classification schemes for PanNET, in 2010 the American Joint Committee on Cancer (AJCC) introduced its first TNM 5 which is derived from the staging classification for exocrine pancreatic adenocarcinomas. The European Neuroendocrine Tumor Society (ENETS) also proposed its TNM staging system. 6 However, direct head-to-head comparison of these different systems in outcome prediction has not been performed. Investigation on the expression of Ki-67 proliferation antigen in pancreatic neuroendocrine neoplasms has been carried out for over 2 decades, first as an attempt to explain difference in responses to chemotherapy 7 and later as a prognostic marker. 8 MIB-1, the protein product for Ki-67, is a marker for cellular proliferation. 9 MIB-1 protein is present during all active phases of the cell cycle (G 1 , S, G 2 , and mitosis) but is absent in resting cells (G 0 ). Ki-67-based PI has been shown to be a significant prognostic factor in WD PanNET. 10 The objectives of this study were to compare the WHO 2004 and 2010 classifications, the Hochwald grading system, and the AJCC and ENETS staging systems for their predictive power for recurrence-free survival (RFS) in patients with locoregional WD PanNET. We also explored the possibility of combining each system with additional important pathologic features to improve the predictive power in such patients.
MATERIALS AND METHODS

Patients
The study was approved by the Institutional Review Board of the Washington University School of Medicine. Surgical pathology files at the Barnes-Jewish Hospital Department of Pathology were queried for PanNET between 1993 and 2009. The following patients were excluded: patients with multiple endocrine neoplasia 1 syndrome, distant metastasis at the time of diagnosis, tumors arising from duodenum, bile duct, or ampulla of Vater, and insufficient tissue material for study. A total of 75 patients who met the above criteria were enrolled. Pertinent demographics and clinical information, including presenting symptoms (to indicate functionality), were recorded. All patients received regular follow-up, and the follow-up information was retrieved from medical records.
Histopathology Examination
All routine hematoxylin and eosin-stained slides were rereviewed. The following parameters were documented for each case: age, sex, tumor size, lymph node involvement status, margin status, perineural invasion, lymphovascular invasion, necrosis, and mitotic counts [recorded as both per 50 high-power fields (HPFs) and per 
WHO 2004 and WHO 2010 Classification Systems
The WHO 2004 classification divided WD PEN into PEN with BB (confined to the pancreas, nonangioinvasive, no perineural invasion, <2 cm in diameter, <2 mitoses/ 10 HPF, and <2% MIB-1-positive cells), PEN with UB (confined to the pancreas and 1 or more of the following features: Z2 cm in diameter, 2 to 10 mitoses/10 HPF, >2% MIB-1-positive cells, angioinvasion, perineural invasion), and WD neuroendocrine carcinoma (NECs) (gross invasion, metastasis). 11 The WHO 2010 classification divided PanNETs into WD NETs and high-grade NECs (grade 3; G3) on the basis of the mitotic count (using 20/ 10 HPF as the cutoff) or Ki-67 PI (20%). The former was further stratified into grade 1 (G1; 0 to 1 mitosis/10 HPF and Ki-67 PI < 3%) and grade 2 (G3; 2 to 20 mitosis/ 10 HPFs or Ki-67 PI 3% to 20%). 
Hochwald Grading System
Tumor Staging by the AJCC-TNM System
The 2010 AJCC-TNM staging system defines T1 stage as tumor dimensions r2 cm and limited to pancreas, T2 as >2 cm and limited to pancreas, T3 as tumor extending beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery, and T4 as tumor involving the celiac axis or the superior mesenteric artery (unresectable). Nodal status is defined as follows: Nx, regional lymph nodes cannot be assessed; N0, no regional lymph node metastasis; and N1, regional lymph node metastasis. Distant metastasis status is defined as: M0, no distant metastasis; and M1, distant metastasis. Stage IA includes T1N0M0; IB, T2N0M0; IIA, T3N0M0; and IIB, T1-3N1M0. Stage III includes T4N0-1M0. M1 defines stage IV disease. 5
Tumor Staging by the ENETS-TNM System
The ENETS-TNM staging system defines stages as follows: T1 stage, tumor dimensions <2 cm and limited to pancreas; T2, 2 to 4 cm and limited to pancreas; T3, >4 cm but limited to the pancreas or invading the duodenum or bile duct; and T4, tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Nodal status is defined as: NX, regional lymph nodes cannot be assessed; N0, no regional lymph node metastasis; and N1, regional lymph node metastasis. Distant metastasis status is defined as: M0, no distant metastasis; and M1, distant metastasis. Stage I includes T1N0M0; IIa, T2N0M0; IIb, T3N0M0; IIIa, T4N0M0; and IIIb, any TN1M0. M1 defines stage IV disease. 12 
PI Determination by Ki-67 (MIB-1) Immunohistochemistry
One representative tumor paraffin block from each case was used to generate 4-mm-thick unstained sections for Ki-67 (MIB-1) immunohistochemical staining with a prediluted antibody (Ventana Medical Systems, AZ). The immunostaining analyses were performed on a Ventana Benchmark-XT automated stainer using the Ventana ul-traView DAB detection kit. The antigen retrieval was performed using Ventana Tris-based buffer solution CC1, at 37 1C for 16 minutes. One thousand nuclei in the area with the highest density of staining were counted (hotspot) manually by a pathologist blinded to the diagnosis (T.-C.L.), and the percentage of Ki-67-expressing cells was recorded for each case.
Statistic Analysis
The primary outcome of this study was RFS, defined as the time from surgery to death due to disease or time to disease recurrence at local, regional, or distant sites, whichever occurred first. Those patients alive and free of disease were censored at the date of the last contact. RFS was calculated using the Kaplan-Meier method, and comparisons were made using the log rank tests. Univariate and multivariate Cox proportional hazard models were fit to assess the effects of different grading/ staging systems and PI on RFS. The overall predictive ability of each model was then assessed by calculating the concordance index (CI). The value of CI ranges from 0.5 to 1; a value of 1 is indicative of a model with perfect predictive power. All analyses were 2 sided, and significance was set at a P-value of 0.05. Statistical analyses were performed using SAS (SAS Institute, Cary, NC).
RESULTS
There were 36 male and 39 female patients. The mean age at diagnosis was 56 years (range, 17 to 83 y). Although some patients had >1 symptom, the most common presenting symptom was abdominal pain (n = 28), followed by hypoglycemia (n = 11), elevated serum gastrin (n = 4), steatorrhea (n = 4), jaundice (n = 4), and diarrhea (n = 2). Four patients presented with nonspecific symptoms such as nausea, heartburn, weight loss, and dyspnea. Twenty-five patients presented with no symptoms and were found on screening or when following up for other diseases. The mean tumor size was 3.0 cm (range, 0.2 to 14.0 cm). The tumor size distribution was r2 cm: 31, 2.1 to 4 cm: 26, and >4 cm: 18. Lymph node involvement, lymphovascular invasion, perineural invasion, and positive resection margin were seen in 24 (24/62, lymph node dissection was not performed in 13), 25, 19, and 11 patients, respectively ( Table 1) . Areas of tumor necrosis were seen in 15 cases. The mean follow-up was 79 months (median 69 mo; range, 1 to 212 mo). During the follow-up, 20 developed recurrence (median time to recurrence 30 mo).
Pathologic Features Predictive of RFS
Among these parameters, tumor size (P = 0.0008), lymph node involvement (P = 0.0073), lymphovascular invasion (P = 0.0222), perineural invasion (P = 0.0002), and tumor necrosis (P < 0.0001) were significantly predictive of RFS, whereas age, sex, and positive surgical margin were not (P = 0.6036, 0.2813, and 0.1944, respectively). In this subset of patients with localized disease, functional status of the tumor did not correlate with RFS (P = 0.5189 between functional vs. nonfunctional tumors).
No mitotic activity was seen in 43 (57%) tumors. The mitotic figures in the remaining 32 tumors ranged from 1 to 19 per 50 HPF (mean 3.8, median 2). The mean Ki-67 PI was 8.1% (median 3.9%; range, 0.2% to 65.6%; >10% in 15 tumors). The Ki-67 PI had a better predictive ability on RFS when it was modeled as a continuous variable (CI = 0.7045) than as a categorical variable using 5% and 10% as the cutoff (r5% vs. 5% to 10% vs. >10%, CI = 0.6641).
Comparison of the WHO 2004 and 2010 Classifications, the Hochwald Grading System, and AJCC and ENETS Staging Systems in Predicting RFS
According to the WHO 2004 classification, 16 of 75 patients had "WD PEN with BB," 35 of 75 had "WD PEN with UB," and 24 had "WD endocrine carcinomas (WDCA)." WDCAs had a significantly shorter RFS compared with both BB and UB groups (P = 0.0057). The median RFS for WDCA patients was 51 months, and the median RFS for both the BB and UB groups were undefined. There was, however, no significant difference in RFS between the BB and UB groups (P = 0.3639; Fig. 1A ). The CI for the WHO 2004 classification in predicting RFS was 0.6361. Analyzing the same data set using the WHO 2010 classification, 26 of 75 patients had G1 tumors, 41 of 75 patients had G2 tumors, and 8 patients had G3 tumors (NEC). The median RFS for G1 and G2 groups were undefined, whereas that of G3 was 25.5 months, ( Fig. 1B ; P < 0.0001). The CI for the WHO 2010 classification in predicting RFS was 0.6735.
Using the Hochwald grading system, 47 (63%) Pan-NETs were categorized as low grade and 28 (37%) were categorized as intermediate grade. Recurrence was observed in 5 (11%) patients in the former and in 15 (54%) patients in the latter. Patients with low-grade tumors had a significantly prolonged RFS compared with those with intermediate grade tumors (P < 0.0001; Fig. 2 ). The median RFS was 51 months in the former group, and it was not defined in the latter. The CI for the Hochwald grading system to predict RFS was 0.6851.
Thirteen patients did not undergo lymph node dissection in the resected specimen and were excluded from the AJCC and ENETS-TNM analysis. Of the remaining 62 patients, by AJCC staging, 19 had stage IA, 10 had stage IB, 10 had stage IIA, and 23 had stage IIB disease. No patient had stage III disease. As shown in Figure 3A , patients with stage IIA disease had an RFS of 58 months and those with stage IIB disease had an RFS of 52 months, whereas those with stages IA and IB were not defined (P = 0.0188). It is noteworthy that there was no statistical significance in RFS between stage IA and IB diseases (P = 0.9155). The CI for AJCC stage in predicting RFS was 0.6495. By the ENETS staging system,
Combining Grading/Staging Systems With Ki-67 PI
We further explored whether incorporating grading or staging system with Ki-67 PI can improve the predictive accuracy of RFS. As Ki-67 PI was part of the WHO 2004 and WHO 2010 classification criteria, analysis by combining Ki-67 PI and the WHO 2004 and 2010 classifications could not be performed. The CI was 0.7946, 0.7528, and 0.7774 when Ki-67 PI was combined with the Hochwald grading system, the AJCC staging system, and the ENETS staging system, respectively. The CI of WHO 2010 classification was increased from 0.6735 to 0.7447 when the status of necrosis was also added to the analysis. When combined with necrosis, the CI of AJCC staging increased to 0.7522 and that of ENETS staging increased to 0.7645; however, none of these surpass the combination of Hochwald grading system or ENETS staging and KI-67 PI ( Table 2 ).
DISCUSSION
Stratification of PanNET has evolved over the last decade. In 2002, Hochwald et al 3 proposed a grading system based on mitotic count and necrosis. Subsequently, WHO adopted 2 classification systems in 2004 and 2010, respectively. 3, 4 In addition, in 2010 AJCC introduced its very first staging system for these tumors. 3 In this study, we compared these grading systems and the AJCC and ENETS staging systems for their ability to predict RFS in patients with WD locoregional PanNET. Our data showed that, although all these various systems predicted RFS well, the Hochwald grading system showed the highest predictive power, which was further increased when it was combined with Ki-67 PI. The Hochwald grading system incorporated both mitotic activity and tumor necrosis. In contrast, the WHO 2010 classification applied mitotic count and Ki-67 PI to stratify pancreatic neuroendocrine neoplasms into WD PanNETs and NECs. 4 Our univariate analysis showed that mitotic count, Ki-67 PI, and tumor necrosis were all significant prognostic factors for regional WD PanNETs, and hence it is not surprising that the Hochwald grading system was superior in predicting RFS compared with the WHO 2010 classification, as the former combined 2 significant variables that are not highly correlated, whereas the latter incorporated 2 variables that are highly correlated. Our data also provides justification of the WHO 2010 classification over the WHO 2004 classification (CI = 0.6735 vs. 0.6361). However, WHO 2010 classification does not address the issue that a small percentage of WDNETs defined by mitosis as G1 or G2 (NET) have Ki-67 PI > 20% (8 of 75 in our series of locoregional NETs) and therefore are considered G3 (NEC) but they are not small cell NECs or large cell NECs (in 2010 WHO classification, NECs include small cell NECs and large cell NECs). It is worth noting that the WHO 2004 classification is neither a pure grading nor a pure staging system; it combines elements of both stage and grade into a single classification. However, 1 main issue with the WHO 2004 classification is that no significant difference in RFS was seen between the BB group and the UB group, and thus the clinical relevance of separating these 2 groups was uncertain. Similar results were also observed by other investigators. 13 In many other organs, the AJCC staging remains the most significant prognostic indicator. In our patients with regional WD PanNET, neither the AJCC staging system (CI = 0.6495) nor the ENETS staging system (CI = 0.6642) had a higher CI compared with the Hochwald grading system (CI = 0.6851). The Hochwald grading system has many advantages for daily practice, including its simplicity for use and prognostic strength. 3 Our study showed that it also possesses a higher prognostic prediction power than the WHO classification schemes. A recent study also dem- onstrates that its prediction power is further enhanced when combined with tumor size and metastasis status. 13 However, the requirement for scoring 50 HPFs for mitotic figures can be limiting for smaller tumors. In our population of patients with regional WD PanNETs, the predictive power of the Hochwald grading system can be further improved by combing it with Ki-67. The AJCC staging system incorporates pancreatic endocrine tumors along with other exocrine malignancies, and its correlation with prognosis was recently validated. 14, 15 Our study focused on patients with resectable WD PanNET, and thus, all stage IV and T4 (stage III) patients were excluded. Our study shows that stage II patients have worse prognosis than patients with stage I diseases. However, no statistical significance was seen between stage IA and IB patients or between stage IIA and IIB patients. A recent large-scale study (including patients with stage IV diseases) indicates that the ENETS staging system is superior to the AJCC system in predicting overall survival. 6 Our data suggest that for locoregional PanNET, the ENETS staging system has a slightly higher predictive power for RFS compared with the AJCC staging system. As the current study focused on patients with regional diseases, the limited number of death events prevented meaningful analysis for overall survival. Therefore, a larger cohort will be needed to study overall survival.
Our study also validates results from previous publications that PI assessed by Ki-67 immunohistochemistry is a powerful, independent prognostic predictor. However, there are limitations to the application of Ki-67 stain. First, the intensity threshold for positivity may be subjective, and it is known that the quality of the stain varies between laboratories. It remains to be established whether interobserver/interinstitutional reproducibility can be established. Second, as the "hotspot" approach is being used, and areas with intensive Ki-67 signals do not always correlate with areas with high mitotic figures on hematoxylin and eosin-stained slides, the selection of areas for immunostaining is crucial. The discrepancy between Ki-67 PI and mitotic count has been recently explored, 16 and more studies are under way to further clarify the issue. Comparison with antibodies recognizing mitotic figures (eg, phosphohistone-H3) will be of particular interest. In addition, given the heterogeneity in PI within the tumor, it is likely that performing Ki-67 stains on tissue microarrays will be inaccurate in determining the PI.
Also noteworthy is that in routine pathology practice, a small proportion of the PanNETs that are resected . RFS analysis stratified by the AJCC and ENETS-TNM staging systems. A, Using the AJCC staging system, patients with stage II disease were associated with reduced RFS compared with patients with stage I disease (P = 0.0188). B, By the ENETS staging system, patients with stage III disease were associated with reduced RFS compared with patients with stage I or II disease (P = 0.0110). are from patients with multiple endocrine neoplasia 1 syndrome. These tumors show distinct morphologic features and genetic alterations. 17, 18 Although these patients were excluded in this analysis, it has been suggested that these patients have superior prognosis compared with patients with sporadic PanNETs. 19, 20 In addition, the mTOR pathway and genes involved in telomerase maintenance (DAXX, ATRX) have been recently identified to play a significant role in up to 40% of PanNETs. 21, 22 It remains to be seen how management of PanNET-harboring mutations in the mTOR pathway will benefit from small molecule-based targeted therapies 23 and how it correlates with our findings. In summary, we have shown that, although the Hochwald grading system, WHO classifications, and AJCC and ENETS staging systems all correlated with RFS in locoregional PanNET, the Hochwald grading system shows the highest CI. Its predictive power can be further improved by combing it with Ki-67 PI.
